A new oncology startup called Ottimo Pharma has been launched by David Epstein, the former CEO of Seagen.
The company aims to develop a novel drug that targets two critical molecular pathways involved in tumor growth and immune evasion: PD-1 and VEGF.
Ottimo Pharma has received backing from the U.K. venture firm Medicxi and plans to seek regulatory approval for its first clinical trial in the near future.
The company's approach involves the development of a bi-functional antibody called jankistomig, which inhibits both PD-1 and the VEGF receptor VEGFR2.
This dual targeting strategy aims to minimize side effects associated with VEGF inhibition.
Ottimo Pharma's innovative approach reflects a broader trend in oncology, where researchers are exploring the synergies of targeting multiple pathways to improve patient outcomes.
Other companies, such as BioNTech and Instil Bio, are also developing similar dual-targeting drugs.
The leadership team of Ottimo Pharma includes industry veterans with extensive experience in the field.
The company's strategic vision is to revolutionize cancer treatment through dual-pathway targeting and deliver on the promise of new therapies for patients.
The success of Ottimo Pharma's approach could have significant implications for the future of cancer immunotherapy and patient care.